Table 3.
Studies using the ADPKD Registry for recruitment
| Date | Criteria | Type of Study | Emails Sent | Emails Opened, % |
|---|---|---|---|---|
| August 2020 | Age 18–65, eGFR 30–90 | Intervention—caloric restriction (NCT04534985) | 612 | 70 |
| October 2020 | Nearing pre-emptive transplant | Intervention—FREEDOM-1 (NCT03995901) | 287 | 68 |
| October 2020 | On dialysis | Observational—academic institution survey | 45 | 58 |
| February 2021 | Pediatric | Observational—pediatric ADPKD registry (NCT04338048) | 16 | 62 |
| March 2021 | Age 25–60, eGFR >60 | Intervention—pravastatin (NCT03273413) | 615 | 70 |
| April 2021 | Age 18–70, eGFR 30–90 | Intervention—bardoxolone methyl (NCT03918447) | 745 | 73 |
| September 2021 | History of aneurysms | Observational—genetic and medical record for academic institution | 37 | 78 |
Email communication with participant cohorts managed by IQVIA platform so as to protect patient name and contact information. eGFR units in ml/min per 1.73 m2. Recruitment efforts initiated upon request by principal investigator. ADPKD, autosomal dominant polycystic kidney disease.